PRESS-RELEASE filed Mar 26, 2026 at 16:05 ET
Spero Therapeutics reported a significant turnaround in financial performance for Q4 and full-year 2025, driven by a 177% YoY revenue increase to $41.3M in the quarter, primarily from collaboration payments with GSK and Pfizer, while R&D expenses dropped 80% due to reduced trial activity. The company also announced that the FDA set a PDUFA date of June 18, 2026, for tebipenem HBr, an investigational oral antibiotic for cUTI, with cash reserves of $40.3M expected to fund operations into 2028.